Lab21 to launch genetic bowel cancer theranostic
This article was originally published in Clinica
Executive Summary
Lab21 is to initiate the UK launch of a screening test to identify patients likely to benefit from new drug for advanced bowel cancer. Patients with metastatic bowel cancer will be tested for the presence of mutations in a particular gene before they are prescribed the drug.